The role of the O-GlcNAc modification in regulating eukaryotic gene expression

Current Signal Transduction Therapy

Volumn 5, Issue 1, 2010, Pages 12-24

  Brimble, Sandii ^a   Wollaston Hayden, Edith E ^a   Teo, Chin Fen ^a   Morris, Andrew C ^a   Wells, Lance ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

O GlcNAc; Post translational modification; Review; Transcriptional regulation

Indexed keywords

ACETYLGLUCOSAMINIDASE; BINDING PROTEIN; COACTIVATING ARGININE METHYLTRANSFERASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METHYLTRANSFERASE; N ACETYLGLUCOSAMINE; N ACETYLGLUCOSAMINYLTRANSFERASE; PROTEIN CRTC2; REGULATOR PROTEIN; TANK BINDING KINASE 1 BINDING PROTEIN 1; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR PDX 1; UNCLASSIFIED DRUG; URIDINE DIPHOSPHATE N ACETYLGLUCOSAMINE;

ARTICLE; CARBOHYDRATE ANALYSIS; CARBOHYDRATE METABOLISM; CHROMATIN ASSEMBLY AND DISASSEMBLY; ENZYME ACTIVITY; ENZYME SUBSTRATE COMPLEX; EUKARYOTE; GENE EXPRESSION REGULATION; GENE MAPPING; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION;

EID: 77951923870     PISSN: 15743624     EISSN: None     Source Type: Journal    
DOI: 10.2174/157436210790226465     Document Type: Article

References (145)

1. Brivanlou AH, Darnell JE, Jr. Signal transduction and the control of gene expression. Science 2002; 295: 813-8.
2. Orphanides G, Reinberg D. A unified theory of gene expression. Cell 2002; 108: 439-51.
3. Levine M, Tjian R. Transcription regulation and animal diversity. Nature 2003; 424: 147-51.
4. Heintzman ND, Ren B. The gateway to transcription: identifying, characterizing and understanding promoters in the eukaryotic genome. Cell Mol Life Sci 2007; 64: 386-400.
5. Khidekel N, Hsieh-Wilson LC. A 'molecular switchboard'-covalent modifications to proteins and their impact on transcription. Org Biomol Chem 2004; 2: 1-7.
6. Torres CR, Hart GW. Topography and polypeptide distribution of terminal N-acetylglucosamine residues on the surfaces of intact lymphocytes. Evidence for O-linked GlcNAc. J Biol Chem 1984; 259: 3308-17.
7. Holt GD, Hart GW. The subcellular distribution of terminal Nacetylglucosamine moieties. Localization of a novel proteinsaccharide linkage, O-linked GlcNAc. J Biol Chem 1986; 261: 8049-57.
8. Holt GD, Haltiwanger RS, Torres CR, Hart GW. Erythrocytes contain cytoplasmic glycoproteins. O-linked GlcNAc on Band 4.1. J Biol Chem 1987; 262: 14847-50.
9. Dehennaut V, Lefebvre T, Sellier C, et al. O-linked Nacetylglucosaminyltransferase inhibition prevents G2/M transition in Xenopus laevis oocytes. J Biol Chem 2007; 282: 12527-36.
10. Dehennaut V, Hanoulle X, Bodart JF, et al. Microinjection of recombinant O-GlcNAc transferase potentiates Xenopus oocytes M-phase entry. Biochem Biophys Res Commun 2008; 369: 539-46.
11. Slawson C, Zachara NE, Vosseller K, Cheung WD, Lane MD, Hart GW. Perturbations in O-linked beta-N-acetylglucosamine protein modification cause severe defects in mitotic progression and cytokinesis. J Biol Chem 2005; 280: 32944-56.
12. Wells L, Vosseller K, Hart GW. A role for N-acetylglucosamine as a nutrient sensor and mediator of insulin resistance. Cell Mol Life Sci 2003; 60: 222-8.
13. Wells L, Vosseller K, Hart GW. Glycosylation of nucleocytoplasmic proteins: signal transduction and O-GlcNAc. Science 2001; 291: 2376-8.
14. Gandy JC, Rountree AE, Bijur GN. Akt1 is dynamically modified with O-GlcNAc following treatments with PUGNAc and insulinlike growth factor-1. FEBS Lett 2006; 580: 3051-8.
15. Vosseller K, Wells L, Lane MD, Hart GW. Elevated nucleocytoplasmic glycosylation by O-GlcNAc results in insulin resistance associated with defects in Akt activation in 3T3-L1 adipocytes. Proc Natl Acad Sci USA 2002; 99: 5313-8.
16. Yang X, Ongusaha PP, Miles PD, et al. Phosphoinositide signalling links O-GlcNAc transferase to insulin resistance. Nature 2008; 451: 964-9.
17. Ohn T, Kedersha N, Hickman T, Tisdale S, Anderson P. A functional RNAi screen links O-GlcNAc modification of ribosomal proteins to stress granule and processing body assembly. Nat Cell Biol 2008; 10: 1224-31.
18. Zachara NE, Hart GW. O-GlcNAc a sensor of cellular state: the role of nucleocytoplasmic glycosylation in modulating cellular function in response to nutrition and stress. Biochim Biophys Acta 2004; 1673: 13-28.
19. Comer FI, Hart GW. O-GlcNAc and the control of gene expression. Biochim Biophys Acta 1999; 1473: 161-71.
20. Dias WB, Hart GW. O-GlcNAc modification in diabetes and Alzheimer's disease. Mol Biosyst 2007; 3: 766-72.
21. Love DC, Hanover JA. The hexosamine signaling pathway: deciphering the "O-GlcNAc code". Sci STKE 2005; 2005: re13.
22. Vosseller K, Sakabe K, Wells L, Hart GW. Diverse regulation of protein function by O-GlcNAc: a nuclear and cytoplasmic carbohydrate post-translational modification. Curr Opin Chem Biol 2002; 6: 851-7.
23. Zachara NE, Hart GW. Cell signaling, the essential role of OGlcNAc! Biochim Biophys Acta 2006; 1761: 599-617.
24. Haltiwanger RS, Holt GD, Hart GW. Enzymatic addition of OGlcNAc to nuclear and cytoplasmic proteins. Identification of a uridine diphospho-N-acetylglucosamine: peptide beta-Nacetylglucosaminyltransferase. J Biol Chem 1990; 265: 2563-8.
25. Kreppel LK, Blomberg MA, Hart GW. Dynamic glycosylation of nuclear and cytosolic proteins. Cloning and characterization of a unique O-GlcNAc transferase with multiple tetratricopeptide repeats. J Biol Chem 1997; 272: 9308-15.
26. Lubas WA, Hanover JA. Functional expression of O-linked GlcNAc transferase. Domain structure and substrate specificity. J Biol Chem 2000; 275: 10983-8.
27. Shafi R, Iyer SP, Ellies LG, et al. The O-GlcNAc transferase gene resides on the X chromosome and is essential for embryonic stem cell viability and mouse ontogeny. Proc Natl Acad Sci USA 2000; 97: 5735-9.
28. Gao Y, Wells L, Comer FI, Parker GJ, Hart GW. Dynamic Oglycosylation of nuclear and cytosolic proteins: cloning and characterization of a neutral, cytosolic beta-N-acetylglucosaminidase from human brain. J Biol Chem 2001; 276: 9838-45.
29. Dong DL, Hart GW. Purification and characterization of an OGlcNAc selective N-acetyl-beta-D-glucosaminidase from rat spleen cytosol. J Biol Chem 1994; 269: 19321-30.
30. Comer FI, Hart GW. O-Glycosylation of nuclear and cytosolic proteins. Dynamic interplay between O-GlcNAc and O-phosphate. J Biol Chem. 2000; 275: 29179-82.
31. Wells L, Kreppel LK, Comer FI, Wadzinski BE, Hart GW. OGlcNAc transferase is in a functional complex with protein phosphatase 1 catalytic subunits. J Biol Chem 2004; 279: 38466-70.
32. Copeland RJ, Bullen JW, Hart GW. Cross-talk between GlcNAcylation and phosphorylation: roles in insulin resistance and glucose toxicity. Am J Physiol Endocrinol Metab 2008; 295: E17- 28.
33. Haltiwanger RS, Blomberg MA, Hart GW. Glycosylation of nuclear and cytoplasmic proteins. Purification and characterization of a uridine diphospho-N-acetylglucosamine: polypeptide beta-Nacetylglucosaminyltransferase. J Biol Chem 1992; 267: 9005-13.
34. Haltiwanger RS, Grove K, Philipsberg GA. Modulation of Olinked N-acetylglucosamine levels on nuclear and cytoplasmic proteins using the peptide O-GlcNAc-beta-N-acetylglucosaminidase inhibitor O-(2-acetamido-2-deoxy-D-glucopyranosylidene) amino-N-phenylcarbamate. J Biol Chem 1998; 273: 3611-7.
35. Macauley MS, Whitworth GE, Debowski AW, Chin D, Vocadlo DJ. O-GlcNAcase uses substrate-assisted catalysis: kinetic analysis and development of highly selective mechanism-inspired inhibitors. J Biol Chem 2005; 280: 25313-22.
36. Dorfmueller HC, Borodkin VS, Schimpl M, Shepherd SM, Shpiro NA, van Aalten DM. GlcNAcstatin: a picomolar, selective OGlcNAcase inhibitor that modulates intracellular O-glcNAcylation levels. J Am Chem Soc 2006; 128: 16484-5.
37. Dorfmueller HC, Borodkin VS, Schimpl M, van Aalten DM. GlcNAcstatins are nanomolar inhibitors of human O-GlcNAcase inducing cellular hyper-O-GlcNAcylation. Biochem J 2009; 420: 221-7.
38. Gross BJ, Swoboda JG, Walker S. A strategy to discover inhibitors of O-linked glycosylation. J Am Chem Soc 2008; 130: 440-1.
39. Vosseller K, Trinidad JC, Chalkley RJ, et al. O-linked Nacetylglucosamine proteomics of postsynaptic density preparations using lectin weak affinity chromatography and mass spectrometry. Mol Cell Proteomics 2006; 5: 923-34.
40. Khidekel N, Ficarro SB, Peters EC, Hsieh-Wilson LC. Exploring the O-GlcNAc proteome: direct identification of O-GlcNAcmodified proteins from the brain. Proc Natl Acad Sci USA 2004; 101: 13132-7.
41. Khidekel N, Ficarro SB, Clark PM, et al. Probing the dynamics of O-GlcNAc glycosylation in the brain using quantitative proteomics. Nat Chem Biol 2007; 3: 339-48.
42. Wells L, Vosseller K, Cole RN, Cronshaw JM, Matunis MJ, Hart GW. Mapping sites of O-GlcNAc modification using affinity tags for serine and threonine post-translational modifications. Mol Cell Proteomics 2002; 1: 791-804.
43. Issad T, Kuo M. O-GlcNAc modification of transcription factors, glucose sensing and glucotoxicity. Trends Endocrinol Metab 2008; 19: 380-9.
44. Zachara NE. Detecting the "O-GlcNAc-ome"; detection, purification, and analysis of O-GlcNAc modified proteins. Methods Mol Biol 2009; 534: 251-79.
45. Hanover JA, Cohen CK, Willingham MC, Park MK. O-linked Nacetylglucosamine is attached to proteins of the nuclear pore. Evidence for cytoplasmic and nucleoplasmic glycoproteins. J Biol Chem 1987; 262: 9887-94.
46. Snow CM, Senior A, Gerace L. Monoclonal antibodies identify a group of nuclear pore complex glycoproteins. J Cell Biol 1987; 104: 1143-56.
47. Comer FI, Hart GW. Reciprocity between O-GlcNAc and Ophosphate on the carboxyl terminal domain of RNA polymerase II. Biochemistry 2001; 40: 7845-52.
48. Khidekel N, Arndt S, Lamarre-Vincent N, et al. A chemoenzymatic approach toward the rapid and sensitive detection of O-GlcNAc posttranslational modifications. J Am Chem Soc 2003; 125: 16162-3.
49. Vocadlo DJ, Hang HC, Kim EJ, Hanover JA, Bertozzi CR. A chemical approach for identifying O-GlcNAc-modified proteins in cells. Proc Natl Acad Sci USA 2003; 100: 9116-21.
50. Saxon E, Bertozzi CR. Cell surface engineering by a modified Staudinger reaction. Science 2000; 287: 2007-10.
51. Whelan SA, Hart GW. Identification of O-GlcNAc sites on proteins. Methods Enzymol 2006; 415: 113-33.
52. Nandi A, Sprung R, Barma DK, Zhao Y, Kim SC, Falck JR. Global identification of O-GlcNAc-modified proteins. Anal Chem 2006; 78: 452-8.
53. Zubarev RA, Kelleher NL, McLafferty FW. Electron capture dissociation of multiply charged protein cations. A nonergodic process. J Am Chem Soc 1998; 120: 3265-6.
54. Syka JE, Coon JJ, Schroeder MJ, Shabanowitz J, Hunt DF. Peptide and protein sequence analysis by electron transfer dissociation mass spectrometry. Proc Natl Acad Sci USA 2004; 101: 9528-33.
55. Mikesh LM, Ueberheide B, Chi A, et al. The utility of ETD mass spectrometry in proteomic analysis. Biochim Biophys Acta 2006; 1764: 1811-22.
56. Wiesner J, Premsler T, Sickmann A. Application of electron transfer dissociation (ETD) for the analysis of posttranslational modifications. Proteomics 2008; 8: 4466-83.
57. Viner RI, Zhang T, Second T, Zabrouskov V. Quantification of post-translationally modified peptides of bovine alpha-crystallin using tandem mass tags and electron transfer dissociation. J Proteomics 2009; 72: 874-85.
58. O'Malley BW, Qin J, Lanz RB. Cracking the coregulator codes. Curr Opin Cell Biol 2008; 20: 310-5.
59. Whitmarsh AJ, Davis RJ. Regulation of transcription factor function by phosphorylation. Cell Mol Life Sci 2000; 57: 1172-83.
60. Holmberg CI, Tran SE, Eriksson JE, Sistonen L. Multisite phosphorylation provides sophisticated regulation of transcription factors. Trends Biochem Sci 2002; 27: 619-27.
61. Lyst MJ, Stancheva I. A role for SUMO modification in transcriptional repression and activation. Biochem Soc Trans 2007; 35: 1389-92.
62. Spange S, Wagner T, Heinzel T, Kramer OH. Acetylation of nonhistone proteins modulates cellular signalling at multiple levels. Int J Biochem Cell Biol 2009; 41: 185-98.
63. Clapier CR, Cairns BR. The Biology of Chromatin Remodeling Complexes. Annu Rev Biochem 2009; 78: 273-304
64. Lee TI, Young RA. Transcription of eukaryotic protein-coding genes. Annu Rev Genet 2000; 34: 77-137.
65. Zhang Y, Reinberg D. Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. Genes Dev 2001; 15: 2343-60.
66. Yang X, Zhang F, Kudlow JE. Recruitment of O-GlcNAc transferase to promoters by corepressor mSin3A: coupling protein O-GlcNAcylation to transcriptional repression. Cell 2002; 110: 69- 80.
67. Fujiki R, Chikanishi T, Hashiba W, et al. GlcNAcylation of a histone methyltransferase in retinoic-acid-induced granulopoiesis. Nature 2009; 459: 455-9.
68. Kelly WG, Hart GW. Glycosylation of chromosomal proteins: localization of O-linked N-acetylglucosamine in Drosophila chromatin. Cell 1989 21; 57: 243-51.
69. Dannenberg JH, David G, Zhong S, van der Torre J, Wong WH, Depinho RA. mSin3A corepressor regulates diverse transcriptional networks governing normal and neoplastic growth and survival. Genes Dev 2005; 19: 1581-95.
70. Shaw P, Freeman J, Bovey R, Iggo R. Regulation of specific DNA binding by p53: evidence for a role for O-glycosylation and charged residues at the carboxy-terminus. Oncogene 1996; 12: 921- 30.
71. Yang WH, Kim JE, Nam HW, et al. Modification of p53 with Olinked N-acetylglucosamine regulates p53 activity and stability. Nat Cell Biol 2006; 8: 1074-83.
72. Murphy M, Ahn J, Walker KK, et al. Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev 1999; 13: 2490-501.
73. Yao D, Taguchi T, Matsumura T, et al. High glucose increases angiopoietin-2 transcription in microvascular endothelial cells through methylglyoxal modification of mSin3A. J Biol Chem 2007; 282: 31038-45.
74. Corden JL. Tails of RNA polymerase II. Trends Biochem Sci 1990; 15: 383-7.
75. Kelly WG, Dahmus ME, Hart GW. RNA polymerase II is a glycoprotein. Modification of the COOH-terminal domain by OGlcNAc. J Biol Chem 1993; 268: 10416-24.
76. Desterro JM, Rodriguez MS, Hay RT. Regulation of transcription factors by protein degradation. Cell Mol Life Sci 2000; 57: 1207- 19.
77. Ravid T, Hochstrasser M. Diversity of degradation signals in the ubiquitin-proteasome system. Nat Rev Mol Cell Biol 2008; 9: 679- 90.
78. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 2002; 82: 373-428.
79. Zhang F, Su K, Yang X, Bowe DB, Paterson AJ, Kudlow JE. OGlcNAc modification is an endogenous inhibitor of the proteasome. Cell 2003; 115: 715-25.
80. Wierstra I. Sp1: Emerging roles-Beyond constitutive activation of TATA-less housekeeping genes. Biochem Biophys Res Commun 2008; 372: 1-13.
81. Jackson SP, Tjian R. O-glycosylation of eukaryotic transcription factors: implications for mechanisms of transcriptional regulation. Cell 1988; 55: 125-33.
82. Han I, Kudlow JE. Reduced O glycosylation of Sp1 is associated with increased proteasome susceptibility. Mol Cell Biol 1997; 17: 2550-8.
83. Sumegi M, Hunyadi-Gulyas E, Medzihradszky KF, Udvardy A. 26S proteasome subunits are O-linked N-acetylglucosaminemodified in Drosophila melanogaster. Biochem Biophys Res Commun 2003; 312: 1284-9.
84. Cheng X, Hart GW. Alternative O-glycosylation/O-phosphorylation of serine-16 in murine estrogen receptor beta: posttranslational regulation of turnover and transactivation activity. J Biol Chem 2001; 276: 10570-5.
85. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev 2000; 14: 2501-14.
86. Cheng X, Cole RN, Zaia J, Hart GW. Alternative O-glycosylation/O-phosphorylation of the murine estrogen receptor beta. Biochemistry 2000; 39: 11609-20.
87. Chou TY, Dang CV, Hart GW. Glycosylation of the c-Myc transactivation domain. Proc Natl Acad Sci USA 1995; 92: 4417- 21.
88. Chou TY, Hart GW, Dang CV. c-Myc is glycosylated at threonine 58, a known phosphorylation site and a mutational hot spot in lymphomas. J Biol Chem 1995; 270: 18961-5.
89. Yustein JT, Dang CV. Biology and treatment of Burkitt's lymphoma. Curr Opin Hematol 2007; 14: 375-81.
90. Vervoorts J, Luscher-Firzlaff J, Luscher B. The ins and outs of MYC regulation by posttranslational mechanisms. J Biol Chem 2006; 281: 34725-9.
91. Adhikary S, Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol 2005; 6: 635-45.
92. Kuiper GG, Gustafsson JA. The novel estrogen receptor-beta subtype: potential role in the cell- and promoter-specific actions of estrogens and anti-estrogens. FEBS Lett 1997; 410: 87-90.
93. Zhao C, Dahlman-Wright K, Gustafsson JA. Estrogen receptor beta: an overview and update. Nucl Recept Signal 2008; 6: e003.
94. Grisouard J, Medunjanin S, Hermani A, Shukla A, Mayer D. Glycogen synthase kinase-3 protects estrogen receptor alpha from proteasomal degradation and is required for full transcriptional activity of the receptor. Mol Endocrinol 2007; 21: 2427-39.
95. Reid G, Hubner MR, Metivier R, et al. Cyclic, proteasomemediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. Mol Cell 2003; 11: 695-707.
96. Picard N, Charbonneau C, Sanchez M, et al. Phosphorylation of activation function-1 regulates proteasome-dependent nuclear mobility and E6-associated protein ubiquitin ligase recruitment to the estrogen receptor beta. Mol Endocrinol 2008; 22: 317-30.
97. Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer 2009; 9: 95-107.
98. Dentin R, Hedrick S, Xie J, Yates J, 3rd, Montminy M. Hepatic glucose sensing via the CREB coactivator CRTC2. Science 2008; 319: 1402-5.
99. Petersen HV, Jensen JN, Stein R, Serup P. Glucose induced MAPK signalling influences NeuroD1-mediated activation and nuclear localization. FEBS Lett 2002; 528: 241-5.
100. Andrali SS, Qian Q, Ozcan S. Glucose mediates the translocation of NeuroD1 by O-linked glycosylation. J Biol Chem 2007; 282: 15589-96.
101. Sayat R, Leber B, Grubac V, Wiltshire L, Persad S. O-GlcNAcglycosylation of beta-catenin regulates its nuclear localization and transcriptional activity. Exp Cell Res 2008; 314: 2774-87.
102. Koo SH, Flechner L, Qi L, et al. The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature 2005; 437: 1109-11.
103. Dentin R, Liu Y, Koo SH, et al. Insulin modulates gluconeogenesis by inhibition of the coactivator TORC2. Nature 2007; 449: 366-9.
104. Screaton RA, Conkright MD, Katoh Y, et al. The CREB coactivator TORC2 functions as a calcium- and cAMP-sensitive coincidence detector. Cell 2004; 119: 61-74.
105. Andrali SS, Sampley ML, Vanderford NL, Ozcan S. Glucose regulation of insulin gene expression in pancreatic beta-cells. Biochem J 2008; 415: 1-10.
106. Barker N. The canonical Wnt/beta-catenin signalling pathway. Methods Mol Biol 2008; 468: 5-15.
107. Zhu W, Leber B, Andrews DW. Cytoplasmic O-glycosylation prevents cell surface transport of E-cadherin during apoptosis. EMBO J 2001; 20: 5999-6007.
108. Gao Y, Miyazaki J, Hart GW. The transcription factor PDX-1 is post-translationally modified by O-linked N-acetylglucosamine and this modification is correlated with its DNA binding activity and insulin secretion in min6 beta-cells. Arch Biochem Biophys 2003; 415: 155-63.
109. Akimoto Y, Hart GW, Wells L, et al. Elevation of the posttranslational modification of proteins by O-linked N-acetylglucosamine leads to deterioration of the glucose-stimulated insulin secretion in the pancreas of diabetic Goto-Kakizaki rats. Glycobiology 2007; 17: 127-40.
110. Zhang W, Patil S, Chauhan B, et al. FoxO1 regulates multiple metabolic pathways in the liver: effects on gluconeogenic, glycolytic, and lipogenic gene expression. J Biol Chem 2006; 281: 10105-17.
111. Finck BN, Kelly DP. PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J Clin Invest 2006; 116: 615-22.
112. Puigserver P, Rhee J, Donovan J, et al. Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature 2003; 423: 550-5.
113. Barthel A, Schmoll D, Unterman TG. FoxO proteins in insulin action and metabolism. Trends Endocrinol Metab 2005; 16: 183-9.
114. Gross DN, van den Heuvel AP, Birnbaum MJ. The role of FoxO in the regulation of metabolism. Oncogene 2008; 27: 2320-36.
115. Housley MP, Rodgers JT, Udeshi ND, et al. O-GlcNAc regulates FoxO activation in response to glucose. J Biol Chem 2008; 283: 16283-92.
116. Kuo M, Zilberfarb V, Gangneux N, Christeff N, Issad T. Oglycosylation of FoxO1 increases its transcriptional activity towards the glucose 6-phosphatase gene. FEBS Lett 2008; 582: 829-34.
117. Housley MP, Udeshi ND, Rodgers JT, et al. A PGC-1{alpha}-OGlcNAc Transferase Complex Regulates FoxO Transcription Factor Activity in Response to Glucose. J Biol Chem 2009; 284: 5148-57.
118. Yang WH, Park SY, Nam HW, et al. NFkappaB activation is associated with its O-GlcNAcylation state under hyperglycemic conditions. Proc Natl Acad Sci USA 2008; 105: 17345-50.
119. Gewinner C, Hart G, Zachara N, Cole R, Beisenherz-Huss C, Groner B. The coactivator of transcription CREB-binding protein interacts preferentially with the glycosylated form of Stat5. J Biol Chem 2004; 279: 3563-72.
120. Yang X, Su K, Roos MD, Chang Q, Paterson AJ, Kudlow JE. Olinkage of N-acetylglucosamine to Sp1 activation domain inhibits its transcriptional capability. Proc Natl Acad Sci USA 2001; 98: 6611-6.
121. Roos MD, Su K, Baker JR, Kudlow JE. O glycosylation of an Sp1derived peptide blocks known Sp1 protein interactions. Mol Cell Biol 1997; 17: 6472-80.
122. Levy DE, Darnell JE, Jr. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002; 3: 651-62.
123. Korzus E, Torchia J, Rose DW, Xu L, Kurokawa R, McInerney EM, et al. Transcription factor-specific requirements for coactivators and their acetyltransferase functions. Science 1998; 279: 703-7.
124. Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell 2008; 132: 344-62.
125. James LR, Tang D, Ingram A, et al. Flux through the hexosamine pathway is a determinant of nuclear factor kappaB- dependent promoter activation. Diabetes 2002; 51: 1146-56.
126. Kawauchi K, Araki K, Tobiume K, Tanaka N. Loss of p53 enhances catalytic activity of IKKbeta through O-linked beta-Nacetyl glucosamine modification. Proc Natl Acad Sci USA 2009; 106: 3431-6.
127. Kawauchi K, Araki K, Tobiume K, Tanaka N. p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation. Nat Cell Biol 2008; 10: 611-8.
128. Schomer-Miller B, Higashimoto T, Lee YK, Zandi E. Regulation of IkappaB kinase (IKK) complex by IKKgamma-dependent phosphorylation of the T-loop and C terminus of IKKbeta. J Biol Chem 2006; 281: 15268-76.
129. Kreppel LK, Hart GW. Regulation of a cytosolic and nuclear OGlcNAc transferase. Role of the tetratricopeptide repeats. J Biol Chem 1999; 274: 32015-22.
130. Iyer SP, Akimoto Y, Hart GW. Identification and cloning of a novel family of coiled-coil domain proteins that interact with OGlcNAc transferase. J Biol Chem 2003; 278: 5399-409.
131. Cheung WD, Sakabe K, Housley MP, Dias WB, Hart GW. Olinked beta-N-acetylglucosaminyltransferase substrate specificity is regulated by myosin phosphatase targeting and other interacting proteins. J Biol Chem 2008; 283: 33935-41.
132. Stallcup MR, Kim JH, Teyssier C, Lee YH, Ma H, Chen D. The roles of protein-protein interactions and protein methylation in transcriptional activation by nuclear receptors and their coactivators. J Steroid Biochem Mol Biol 2003; 85: 139-45.
133. Iyer SP, Hart GW. Roles of the tetratricopeptide repeat domain in O-GlcNAc transferase targeting and protein substrate specificity. J Biol Chem 2003; 278: 24608-16.
134. Hurtado-Guerrero R, Dorfmueller HC, van Aalten DM. Molecular mechanisms of O-GlcNAcylation. Curr Opin Struct Biol 2008; 18: 551-7.
135. Whisenhunt TR, Yang X, Bowe DB, Paterson AJ, Van Tine BA, Kudlow JE. Disrupting the enzyme complex regulating OGlcNAcylation blocks signaling and development. Glycobiology 2006; 16: 551-63.
136. Verkerk AJ, Pieretti M, Sutcliffe JS, et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 1991; 65: 905-14.
137. Garber K, Smith KT, Reines D, Warren ST. Transcription, translation and fragile X syndrome. Curr Opin Genet Dev 2006; 16: 270-5.
138. Garnon J, Lachance C, Di Marco S, et al. Fragile X-related protein FXR1P regulates proinflammatory cytokine tumor necrosis factor expression at the post-transcriptional level. J Biol Chem 2005; 280: 5750-63.
139. Vietor I, Huber LA. Role of TIS7 family of transcriptional regulators in differentiation and regeneration. Differentiation 2007; 75: 891-7.
140. Vietor I, Vadivelu SK, Wick N, et al. TIS7 interacts with the mammalian SIN3 histone deacetylase complex in epithelial cells. EMBO J 2002; 21: 4621-31.
141. Vietor I, Kurzbauer R, Brosch G, Huber LA. TIS7 regulation of the beta-catenin/Tcf-4 target gene osteopontin (OPN) is histone deacetylase-dependent. J Biol Chem 2005; 280: 39795-801.
142. Wick N, Schleiffer A, Huber LA, Vietor I. Inhibitory effect of TIS7 on Sp1-C/EBPalpha transcription factor module activity. J Mol Biol 2004; 336: 589-95.
143. Ryzhakov G, Randow F. SINTBAD, a novel component of innate antiviral immunity, shares a TBK1-binding domain with NAP1 and TANK. EMBO J 2007; 26: 3180-90.
144. Hiscott J, Nguyen TL, Arguello M, Nakhaei P, Paz S. Manipulation of the nuclear factor-kappaB pathway and the innate immune response by viruses. Oncogene 2006; 25: 6844-67.
145. Hart GW, Housley MP, Slawson C. Cycling of O-linked beta-Nacetylglucosamine on nucleocytoplasmic proteins. Nature 2007; 446: 1017-22.